and costs (mean cost difference $37, 609) were significantly less with pharmacomechanical thrombolysis. There
was no difference in bleeding complications, although patients undergoing pharmacomechanical thrombolysis required fewer transfusions (0.2 vs 1.2 units). The second
small study (n ⫽ 45) similarly demonstrated shorter treatment times (30.3 ⫾ 17.8 vs 56.5 �